UNSPSC 51191964: Tretinoin tocoferil

This classification denotes a differentiation inducer with the molecular formula C49H76O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CTD060B1SS, chemically known as (+-)-(2r*)-2,5,7,8-tetramethyl-2-((4r*,8r*)-4,8,12-trimethyltridecyl)-6-chromanyl retinoate but more generally known as tocoretinate, which bears US NIH Compound Identifier 5282180. European Medicines Agency schedules Tretinoin tocoferil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11247MIG.

UNSPSC 51191964 Tretinoin tocoferil is a Commodity code that in recent state and local procurement activity covers chemical and pharmaceutical supply for municipal utilities and healthcare systems. The code encompasses both specialty chemicals for water treatment operations and multi-source generic pharmaceuticals and over-the-counter products distributed through authorized wholesaler networks to public facilities. Issuing bodies include municipal water authorities and multi-state cooperative purchasing alliances administering statewide and regional government procurement. The City of Meriden, Connecticut, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represent the recent buyers under this code.

The code shows activity concentrated in Connecticut and Minnesota, with MMCAP's cooperative vehicle extending coverage to participating states including Oregon. Representative recent opportunities include the City of Meriden's IFB for sodium bisulfite chemical supply for its Water Pollution Control Facility, with bids due July 29, 2026 (Solicitation B02715), and MMCAP's RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 (Solicitation S1070000015802). The MMCAP procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson—and awards scheduled effective July 1, 2026. Vendors must maintain substantial insurance coverage, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and accept a 3 percent administrative fee on all contract purchases.